Acquired by Agrisera AB was acquired by Olink Holding AB in May 2020, signaling potential integration or collaboration opportunities with Olink proteomics capabilities and distributor networks.

SMB Focus Operating with 11-50 employees and revenue under one million dollars, Agrisera represents a small to mid-sized target with potential for scalable antibody supply partnerships, co-development, or channel partnerships to expand market reach.

Product Depth Specializes in polyclonal and monoclonal antibody production with an extensive catalog of primary and secondary antibodies, offering multiple formats and quantities suitable for bundled sales or cross-sell of related proteomics products.

Tech & Ops Leverages standard enterprise tools (HubSpot, ISO practices, Atlassian) and online ordering, presenting an opportunity to offer enhanced CRM-driven sales outreach, ecommerce enhancements, and logistical services for global customers.

Growth Signals Past focus on antibody solutions and a long industry presence (40 years) suggests established customer trust and repeat purchase behavior, making them a potential candidate for premium support plans, training packages, and high-value contract manufacturing discussions via partners or distributors.